Skip to content
type1.science
Phase 2Not yet recruitingNCT07430332

GLP-1 receptor agonist for stage-1 T1D

What this study tests

Randomized placebo-controlled trial of semaglutide in stage 1 T1D with impaired first-phase insulin secretion. It measures OGTT C-peptide over 12 months; no evidence of delayed stage 3 onset is available.

Editorial review: .

Registry checked: 2026-09-17. Registry’s own update: 2026-02-24.

Source dates appear in the references where available; this record has no dated citation metadata.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Evidence at a glance

Who can enter the study?
Per the registry record, ages 12–70 with stage 1 T1D and impaired or lost first-phase insulin secretion on screening OGTT, without dysglycemia suggesting stage 2 or 3. GLP-1 safety exclusions and BMI cutoffs apply. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
Reported benefit and results
No results posted yet.Read the result sources and their limitations →
Important harms
Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
Research access and approval
Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
What remains uncertain?
Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.

Research status alone does not establish approval, clinical benefit or local availability.

Primary endpoints

  • C-peptide area under the curve during OGTT at 12 months
  • C-peptide area under the curve (AUC) from stimulated C-peptide during OGTT at baseline and 12 months

The full picture

This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.

Sources

  1. [1]